Omalizumab Cuts Down Hospital Visits

Published Online: Friday, July 1, 2005

Patients may benefit from adding omalizumab (Xolair) to their asthma treatment if they have persistent asthma that is not being controlled. For the study, 419 patients with acute asthma were randomly given omalizumab or placebo for 28 weeks. All of the participants were taking high doses of inhaled corticosteroids plus long-acting beta2 agonists, and two thirds were also receiving controller medications, including 22% who were taking oral corticosteroids.

Reporting the findings during the recent annual meeting of the American Academy of Allergy, Asthma, and Immunology, the researchers found that omalizumab was linked with a 26% reduction in the rate of clinically significant asthma exacerbations, compared with placebo. Furthermore, the medication considerably lowered the occurrence of severe asthma attacks and emergency room visits. Lead researcher Phillip Korenblat, MD, said omalizumab led to "meaningful improvement"in asthmarelated quality of life. Omalizumab "should be considered in this group of patients with severe persistent asthma who continue to have unmet needs despite the best available therapy,"he added.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues